Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

REMSleep Holdings has announced that it has received HCPCS approval from the Pricing, Data Analysis and Coding (PDAC) contractor for its DeltaWave nasal pillow system.

It was once feared weight-loss drugs would crush demand for sleep apnoea products. ResMed's December quarter has shown very ...

Medical device company ResMed (NYSE:RMD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share ...

Resmed Inc () has held its Q2 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools ...

The DeltaWave product portfolio expansion was informed by feedback from early adoption partners during REMSleep’s Q4 2025 soft launch. DME providers and sleep laboratories identified specific ...

ResMed’s fourth quarter performance drew a positive market reaction, with management attributing the outperformance to strong global demand for its masks and devices, as well as continued growth in ...

Glacier ENT in Kalispell offers Inspire therapy - a tiny device that helps keep your airway open naturally while you sleep.

The Spanish club's physical trainer Antonio Pintus favours using the K5 masks to measure players' physical condition ...

Q2 FY2026 earnings call recap: 11% revenue growth, margin expansion, AI innovation, and updated 62–63% guidance—read key takeaways now.

If you purchase an independently reviewed product or service through a link on our website, SheKnows may receive an affiliate ...